Sanuwave

Sanuwave is a commercial-stage medical device company focused on shifting the standard of care for chronic wounds through its proprietary non-contact, low-frequency ultrasound (NCLFU) technology. Its flagship UltraMIST® System, cleared by the FDA, is central to the company's 'Energy First™' protocol, aiming to jumpstart stalled healing, reduce pain, and improve patient outcomes. The company's strategy hinges on driving commercial adoption in the massive advanced wound care market while generating robust clinical and economic data to secure broader reimbursement and provider acceptance.

Proprietary Non-Contact, Low-Frequency Ultrasound (NCLFU) delivered via a saline mist to stimulate cellular healing, debride tissue, disrupt biofilm, and enhance perfusion in chronic wounds.

Sanuwave competes with large, diversified wound care companies (e.g., 3M, Smith & Nephew) and other energy-based therapies. Its primary differentiator is the non-contact, pain-free delivery of low-frequency ultrasound via saline mist, which supports its 'Energy First' clinical protocol aimed at early intervention.